Final Phase 1b results presented at World Lung Conference highlight the potential of firmonertinib to address unmet needs in EGFR PACC mutant NSCLC Received FDA IND clearance for ARR-217, a CDH-17 ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback